On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Investigational education entry. Cibinetide received an EMA orphan designation for sarcoidosis; a designation supports development and is not permission to market a treatment. The cited studies do not establish a US-approved product for this catalog entry.
How it is being studied
Cibinetide targets a pathway described as the innate repair receptor. Researchers investigate whether that signaling can affect inflammation and tissue repair. A plausible receptor mechanism is a research rationale; it does not independently prove a clinical benefit. [1]
Orphan designation and approval
EMA granted an orphan designation for development in sarcoidosis. This is separate from marketing authorization and does not certify products offered by other suppliers. [2]
What the evidence shows
Small-fiber neuropathy · randomized trial
In 2017, 64 participants with sarcoidosis-related small-fiber loss and neuropathic pain entered a 28-day trial. One treatment group improved the primary corneal nerve-fiber measure versus placebo. This was a surrogate marker. Pain improved in all groups; the placebo-adjusted pain result highlighted for a subgroup was not statistically significant. The finding does not establish predictable pain relief for other kinds of neuropathy. [3]
Diabetic macular edema · exploratory pilot
A 2020 study enrolled nine people, with eight completing 12 weeks. Average visual acuity, retinal thickness, retinal sensitivity, and tear production did not improve. A vision-related questionnaire score improved, and some individual measures were promising. Without a control group, this cannot demonstrate that cibinetide improves diabetic eye disease. [4]
Glucose and pancreatic-islet research · animals
Experiments in diabetic rats and isolated rat islets found changes in glucose tolerance and insulin release. These were animal experiments. Isolated cells—even human cells in other research—are not the same evidence as a treatment trial in people. This paper does not show that ARA-290 treats human diabetes. [5]
What remains unknown
The studies do not provide a dependable week-by-week recovery timeline, establish long-term benefit across conditions, or validate marketed combinations. A 28-day research period is a study design, not a standard cycle to follow.
Safety
What the small safety sample means
The nine-person eye pilot reported no serious adverse events or detected anti-cibinetide antibodies. That small, short observation cannot exclude uncommon reactions or establish long-term safety. Several authors had financial ties to the developer, which is relevant context when reading the findings. [4]
Interactions and eligibility
The sarcoidosis trial used eligibility restrictions and monitored participants. Those restrictions should not be rewritten as a complete interaction list or universal contraindications. This guide has not established that combinations with BPC-157, TB-500, hormones, or other medicines are compatible or synergistic. [1]
Research formulation versus a marketed vial
The registered trial studied a defined subcutaneous formulation under a research protocol. It does not supply a universal diluent, mixing volume, appearance standard, or storage life for other vials. This guide therefore does not endorse the generic reconstitution instructions shown in other libraries. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [6]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [7]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does nerve-fiber growth prove that symptoms will improve?
No. A tissue measurement can support further research, but everyday function and symptoms need their own convincing results. The pain comparison in the cited 2017 trial was less certain than the corneal nerve-fiber finding.
Can I expect benefits at two, four, or six weeks?
These papers do not establish a reliable personal timeline. Kairo shows the study duration and what was measured instead of predicting when you will feel a benefit.
Is an orphan designation an approval?
No. It is a regulatory development designation for a rare condition. It does not by itself demonstrate effectiveness or authorize a marketed medicine.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisClinicalTrials.gov · NCT02039687 · trial design
- EU/3/13/1191: orphan designation for treatment of sarcoidosisEMA · orphan designation is not marketing authorization
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain2017 · randomized phase 2b · 64 participants
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema2020 · open-label pilot · 9 participants
- ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats2016 · animal and isolated-islet experiments
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.